SCHEMBL24317491

SCHEMBL24317491

CONc1cccc2ncnc(Cl)c12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 1/20 0.41
PDE4B Q07343 1/20 0.41
PDE4C Q08493 1/20 0.41
PDE4D Q08499 1/20 0.41
EGFR P00533 4/20 0.36
RET P07949 1/20 0.35
KIF5B P33176 1/20 0.35
KDR P35968 1/20 0.35
KMT2A Q03164 4/20 0.35
MEN1 O00255 3/20 0.35
HPGD P15428 2/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
AURKA O14965 1/20 0.34
FGFR2 P21802 1/20 0.34
KCNA5 P22460 1/20 0.33
SRC P12931 3/20 0.33
DYRK1A Q13627 3/20 0.33
DYRK1B Q9Y463 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30782464 0.75 KMT2A (0.54) PDE4APDE4BPDE4CPDE4DEGFR
SCHEMBL1478679 0.75 KMT2A (0.54) PDE4APDE4BPDE4CPDE4DEGFR
SCHEMBL30530531 0.74 EGFR (0.55) EGFRKMT2AMEN1AURKANR2F2
SCHEMBL24329543 0.74 EGFR (0.55) EGFRKMT2AMEN1AURKANR2F2
SCHEMBL1014181 0.72 PDE4A (0.48) PDE4APDE4BPDE4CPDE4DKMT2A
SCHEMBL8808732 0.71 PDE4A (0.52) PDE4APDE4BPDE4CPDE4DEGFR
SCHEMBL17823198 0.69 ENPP1 (0.48) PDE4APDE4BPDE4CPDE4DEGFR
SCHEMBL1192699 0.69 KDM1A (0.45) PDE4APDE4BPDE4CPDE4DEGFR
SCHEMBL24329542 0.69 PARP1 (0.58) HPGDNPC1RAB9ADYRK1AMAPT
SCHEMBL9267455 0.68 PDE4A (0.48) PDE4APDE4BPDE4CPDE4DEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022081927-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY C4 THERAPEUTICS, INC. (US) 2022-04-21 WO disclosed